Connect Biopharma Holdings
CNTB
16 hedge funds and large institutions have $2.45M invested in Connect Biopharma Holdings in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
2% more capital invested
Capital invested by funds: $2.4M → $2.45M (+$46.7K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.49% less ownership
Funds ownership: 4.4% → 2.91% (-1.5%)
6% less funds holding
Funds holding: 17 → 16 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$103K |
| 2 |
Renaissance Technologies
New York
|
+$25.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.3K |
| 4 |
MWA
Monograph Wealth Advisors
Manhattan Beach,
California
|
+$19.7K |
| 5 |
HF
HRT Financial
New York
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$981K |
| 2 |
CL
Choreo LLC
Rockford,
Illinois
|
-$158K |
| 3 |
AC
AlphaCore Capital
La Jolla,
California
|
-$78.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$62K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$40K |
CNTB Hedge Fund Activity: Q3 2025 in Review
16 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q3 2025, worth a combined $2.45M — up 1.9% from $2.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CNTB and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $103K. The largest seller was BML Capital Management, cutting an estimated $981K.
- 16 institutional investors held Connect Biopharma Holdings (CNTB) as of Q3 2025, down from 17 in Q2 2025.
- Funds reported $2.45M of Connect Biopharma Holdings stock for Q3 2025, up 1.9% quarter-over-quarter.
- 5 funds opened new Connect Biopharma Holdings positions in Q3 2025 and 6 closed out, a net change of -1 holder.
- The largest Connect Biopharma Holdings buyer in Q3 2025 was Marshall Wace, an estimated $103K added.
- The largest Connect Biopharma Holdings seller in Q3 2025 was BML Capital Management, an estimated $981K sold.
Based on aggregated 13F filings for Q3 2025.